Chemokines and Viral-Induced Neurologic Disease
趋化因子和病毒引起的神经系统疾病
基本信息
- 批准号:6861286
- 负责人:
- 金额:$ 5.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-12-15 至 2005-11-30
- 项目状态:已结题
- 来源:
- 关键词:IP 10 proteinT lymphocytecentral nervous system disorderschemokinechemokine receptorcomputer data analysisdisease /disorder etiologyflow cytometrygene targetingimmunocytochemistryimmunopathologyinflammationlaboratory mouselight microscopymacrophagemultiple sclerosismurine hepatitis virusmyelinationnervous system infectionscintillation countertransfection /expression vectorvirus diseases
项目摘要
The underlying pathological mechanisms contributing to the human demyelinating disease Multiple Sclerosis (MS) are poorly understood. Current hypothesis indicate that the etiology of MS is multifactorial and includes the genetic background of the individual as well as environmental influences e.g. viral. Infection of susceptible mice with mouse hepatitis virus (MHV, a positive-strand RNA virus in the Coronaviridae family) results in a chronic demyelinating disease. Animals develop ascending hind-limb paralysis accompanied by mononuclear by mononuclear cell infiltration into the CNS and myelin destruction. As such, the MHV-model of demyelination is considered an excellent model to study the immunopathological mechanisms contributing to demyelination in patients with MS. T cells and macrophages are important contributors to the pathogenesis of MHV-induced demyelination as well as demyelination in MS patients. The long-range goal of this research proposal is to better understand the molecular mechanisms that regulate entry of T cells and macrophages into the CNS. To this end, studies are designed to evaluate the contributions of chemokines and chemokine receptors in the pathogenesis of MHV-induced demyelination. This is particularly relevant as recent studies have implicated chemokines and chemokine receptors in the pathogenesis of MS. Novel strategies designed to accomplish this goal include i) the use of anti-chemokine antibodies that specifically neutralize chemokine activity in vivo within MHV-infected mice, ii) utilization of chemokine and chemokine receptor knock-out (-/- ) mice to evaluate the development of neurologic disease following MHV infection of the CNS, and iii) the instillation of replication deficient adenovirus vectors that express recombinant mouse chemokines into the CNS of mice to better understand the contributions of these molecules in contributing to neuroinflammation and demyelination. Together, these studies will extend our current understanding of how chemokines and their receptors control CNS inflammation and demyelination. Further, the data obtained from these experiments may identify potential targets for therapeutic treatment of humans with MS. Finally, the data obtained from these experiments may identify potential targets for therapeutic treatment of humans with MS. Finally, as chemokines have been implicated in numerous inflammatory pathologies, findings obtained from these studies will be relevant to other human inflammatory diseases.
导致人类脱髓鞘疾病多发性硬化症(MS)的潜在病理机制知之甚少。目前的假设表明MS的病因是多因素的,包括个体的遗传背景以及环境影响,例如病毒。易感小鼠感染小鼠肝炎病毒(MHV,冠状病毒科的一种正链RNA病毒)会导致慢性脱髓鞘疾病。动物发生上行性后肢麻痹,伴有单核细胞浸润到CNS和髓鞘破坏。因此,脱髓鞘的MHV模型被认为是研究有助于MS患者脱髓鞘的免疫病理学机制的极好模型。T细胞和巨噬细胞是MS患者中MHV诱导的脱髓鞘以及脱髓鞘的发病机制的重要贡献者。这项研究计划的长期目标是更好地了解调节T细胞和巨噬细胞进入CNS的分子机制。为此,研究旨在评估趋化因子和趋化因子受体在MHV诱导的脱髓鞘发病机制中的作用。这是特别相关的,因为最近的研究已经将趋化因子和趋化因子受体牵涉到MS的发病机制中。设计用于实现该目标的新策略包括i)使用抗趋化因子抗体,其特异性中和MHV感染小鼠体内的趋化因子活性,ii)利用趋化因子和趋化因子受体敲除(-/-)小鼠以评价CNS的MHV感染后神经系统疾病的发展,以及iii)将表达重组小鼠趋化因子的复制缺陷型腺病毒载体滴注到小鼠的CNS中,以更好地理解这些分子在导致神经炎症和脱髓鞘。总之,这些研究将扩展我们目前对趋化因子及其受体如何控制CNS炎症和脱髓鞘的理解。最后,从这些实验中获得的数据可以确定潜在的目标,用于治疗性治疗的人MS。最后,从这些实验中获得的数据可以确定潜在的目标,用于治疗性治疗的人MS。最后,由于趋化因子已涉及许多炎症病理,从这些研究中获得的发现将与其他人类炎症性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas E Lane其他文献
Thomas E Lane的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas E Lane', 18)}}的其他基金
FASEB's "The Translational Neuroimmunology Conference: From Mechanisms to Therapeutics."
FASEB 的“转化神经免疫学会议:从机制到治疗学”。
- 批准号:
10065269 - 财政年份:2020
- 资助金额:
$ 5.56万 - 项目类别:
Defining mechanisms of disease and repair in a viral model of multiple sclerosis
定义多发性硬化症病毒模型中的疾病和修复机制
- 批准号:
10640816 - 财政年份:2020
- 资助金额:
$ 5.56万 - 项目类别:
Chemokines and Viral-Induced Neurologic Disease
趋化因子和病毒引起的神经系统疾病
- 批准号:
10090528 - 财政年份:2020
- 资助金额:
$ 5.56万 - 项目类别:
Human neural precursor cell-mediated therapy in a viral model of demyelination
脱髓鞘病毒模型中的人神经前体细胞介导的治疗
- 批准号:
10076583 - 财政年份:2020
- 资助金额:
$ 5.56万 - 项目类别:
Human neural precursor cell-mediated therapy in a viral model of demyelination
脱髓鞘病毒模型中的人神经前体细胞介导的治疗
- 批准号:
8874463 - 财政年份:2015
- 资助金额:
$ 5.56万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8885924 - 财政年份:2011
- 资助金额:
$ 5.56万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8799481 - 财政年份:2011
- 资助金额:
$ 5.56万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8291218 - 财政年份:2011
- 资助金额:
$ 5.56万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8490463 - 财政年份:2011
- 资助金额:
$ 5.56万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8152289 - 财政年份:2011
- 资助金额:
$ 5.56万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 5.56万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 5.56万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 5.56万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 5.56万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 5.56万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 5.56万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 5.56万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 5.56万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 5.56万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 5.56万 - 项目类别:
Discovery Grants Program - Individual